As the global economy recovers in 2021 and the supply of the industrial chain improves, the Restless Legs Syndrome market will undergo major changes. According to the latest research, the market size of the Restless Legs Syndrome industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.
The global Restless Legs Syndrome industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.
The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global Restless Legs Syndrome market during the next few years. The global Restless Legs Syndrome market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.
This report presents a comprehensive overview, market shares, and growth opportunities of Restless Legs Syndrome market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Pharmacological Therapy
Non-Pharmacological Therapy
Segmentation by end user: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Below 35 Years Old
From 35 to 50 Years Old
Above 50 Years Old
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Boehringer Ingelheim GmbH
UCB SA
Astellas
Arbor Pharmaceuticals
GlaxoSmithKline plc.
Ligand Pharmaceuticals Incorporated
axxonis Pharma AG
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
Omeros Corporation
Manhattan Pharmaceuticals
Table of Content
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Restless Legs Syndrome Market Size 2017-2028
2.1.2 Restless Legs Syndrome Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Restless Legs Syndrome Segment by Type
2.2.1 Pharmacological Therapy
2.2.2 Non-Pharmacological Therapy
2.3 Restless Legs Syndrome Market Size by Type
2.3.1 Restless Legs Syndrome Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Restless Legs Syndrome Market Size Market Share by Type (2017-2022)
2.4 Restless Legs Syndrome Segment by End User
2.4.1 Below 35 Years Old
2.4.2 From 35 to 50 Years Old
2.4.3 Above 50 Years Old
2.5 Restless Legs Syndrome Market Size by End User
2.5.1 Restless Legs Syndrome Market Size CAGR by End User (2017 VS 2022 VS 2028)
2.5.2 Global Restless Legs Syndrome Market Size Market Share by End User (2017-2022)
3 Restless Legs Syndrome Market Size by Player
3.1 Restless Legs Syndrome Market Size Market Share by Players
3.1.1 Global Restless Legs Syndrome Revenue by Players (2020-2022)
3.1.2 Global Restless Legs Syndrome Revenue Market Share by Players (2020-2022)
3.2 Global Restless Legs Syndrome Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Restless Legs Syndrome by Regions
4.1 Restless Legs Syndrome Market Size by Regions (2017-2022)
4.2 Americas Restless Legs Syndrome Market Size Growth (2017-2022)
4.3 APAC Restless Legs Syndrome Market Size Growth (2017-2022)
4.4 Europe Restless Legs Syndrome Market Size Growth (2017-2022)
4.5 Middle East & Africa Restless Legs Syndrome Market Size Growth (2017-2022)
5 Americas
5.1 Americas Restless Legs Syndrome Market Size by Country (2017-2022)
5.2 Americas Restless Legs Syndrome Market Size by Type (2017-2022)
5.3 Americas Restless Legs Syndrome Market Size by End User (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Restless Legs Syndrome Market Size by Region (2017-2022)
6.2 APAC Restless Legs Syndrome Market Size by Type (2017-2022)
6.3 APAC Restless Legs Syndrome Market Size by End User (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Restless Legs Syndrome by Country (2017-2022)
7.2 Europe Restless Legs Syndrome Market Size by Type (2017-2022)
7.3 Europe Restless Legs Syndrome Market Size by End User (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Restless Legs Syndrome by Region (2017-2022)
8.2 Middle East & Africa Restless Legs Syndrome Market Size by Type (2017-2022)
8.3 Middle East & Africa Restless Legs Syndrome Market Size by End User (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Restless Legs Syndrome Market Forecast
10.1 Global Restless Legs Syndrome Forecast by Regions (2023-2028)
10.1.1 Global Restless Legs Syndrome Forecast by Regions (2023-2028)
10.1.2 Americas Restless Legs Syndrome Forecast
10.1.3 APAC Restless Legs Syndrome Forecast
10.1.4 Europe Restless Legs Syndrome Forecast
10.1.5 Middle East & Africa Restless Legs Syndrome Forecast
10.2 Americas Restless Legs Syndrome Forecast by Country (2023-2028)
10.2.1 United States Restless Legs Syndrome Market Forecast
10.2.2 Canada Restless Legs Syndrome Market Forecast
10.2.3 Mexico Restless Legs Syndrome Market Forecast
10.2.4 Brazil Restless Legs Syndrome Market Forecast
10.3 APAC Restless Legs Syndrome Forecast by Region (2023-2028)
10.3.1 China Restless Legs Syndrome Market Forecast
10.3.2 Japan Restless Legs Syndrome Market Forecast
10.3.3 Korea Restless Legs Syndrome Market Forecast
10.3.4 Southeast Asia Restless Legs Syndrome Market Forecast
10.3.5 India Restless Legs Syndrome Market Forecast
10.3.6 Australia Restless Legs Syndrome Market Forecast
10.4 Europe Restless Legs Syndrome Forecast by Country (2023-2028)
10.4.1 Germany Restless Legs Syndrome Market Forecast
10.4.2 France Restless Legs Syndrome Market Forecast
10.4.3 UK Restless Legs Syndrome Market Forecast
10.4.4 Italy Restless Legs Syndrome Market Forecast
10.4.5 Russia Restless Legs Syndrome Market Forecast
10.5 Middle East & Africa Restless Legs Syndrome Forecast by Region (2023-2028)
10.5.1 Egypt Restless Legs Syndrome Market Forecast
10.5.2 South Africa Restless Legs Syndrome Market Forecast
10.5.3 Israel Restless Legs Syndrome Market Forecast
10.5.4 Turkey Restless Legs Syndrome Market Forecast
10.5.5 GCC Countries Restless Legs Syndrome Market Forecast
10.6 Global Restless Legs Syndrome Forecast by Type (2023-2028)
10.7 Global Restless Legs Syndrome Forecast by End User (2023-2028)
11 Key Players Analysis
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Information
11.1.2 Boehringer Ingelheim GmbH Restless Legs Syndrome Product Offered
11.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Boehringer Ingelheim GmbH Main Business Overview
11.1.5 Boehringer Ingelheim GmbH Latest Developments
11.2 UCB SA
11.2.1 UCB SA Company Information
11.2.2 UCB SA Restless Legs Syndrome Product Offered
11.2.3 UCB SA Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 UCB SA Main Business Overview
11.2.5 UCB SA Latest Developments
11.3 Astellas
11.3.1 Astellas Company Information
11.3.2 Astellas Restless Legs Syndrome Product Offered
11.3.3 Astellas Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Astellas Main Business Overview
11.3.5 Astellas Latest Developments
11.4 Arbor Pharmaceuticals
11.4.1 Arbor Pharmaceuticals Company Information
11.4.2 Arbor Pharmaceuticals Restless Legs Syndrome Product Offered
11.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Arbor Pharmaceuticals Main Business Overview
11.4.5 Arbor Pharmaceuticals Latest Developments
11.5 GlaxoSmithKline plc.
11.5.1 GlaxoSmithKline plc. Company Information
11.5.2 GlaxoSmithKline plc. Restless Legs Syndrome Product Offered
11.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 GlaxoSmithKline plc. Main Business Overview
11.5.5 GlaxoSmithKline plc. Latest Developments
11.6 Ligand Pharmaceuticals Incorporated
11.6.1 Ligand Pharmaceuticals Incorporated Company Information
11.6.2 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Offered
11.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Ligand Pharmaceuticals Incorporated Main Business Overview
11.6.5 Ligand Pharmaceuticals Incorporated Latest Developments
11.7 axxonis Pharma AG
11.7.1 axxonis Pharma AG Company Information
11.7.2 axxonis Pharma AG Restless Legs Syndrome Product Offered
11.7.3 axxonis Pharma AG Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 axxonis Pharma AG Main Business Overview
11.7.5 axxonis Pharma AG Latest Developments
11.8 Kyowa Hakko Kirin Co.
11.8.1 Kyowa Hakko Kirin Co. Company Information
11.8.2 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Offered
11.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Kyowa Hakko Kirin Co. Main Business Overview
11.8.5 Kyowa Hakko Kirin Co. Latest Developments
11.9 Jazz Pharmaceuticals, Inc.
11.9.1 Jazz Pharmaceuticals, Inc. Company Information
11.9.2 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Offered
11.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Jazz Pharmaceuticals, Inc. Main Business Overview
11.9.5 Jazz Pharmaceuticals, Inc. Latest Developments
11.10 Omeros Corporation
11.10.1 Omeros Corporation Company Information
11.10.2 Omeros Corporation Restless Legs Syndrome Product Offered
11.10.3 Omeros Corporation Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Omeros Corporation Main Business Overview
11.10.5 Omeros Corporation Latest Developments
11.11 Manhattan Pharmaceuticals
11.11.1 Manhattan Pharmaceuticals Company Information
11.11.2 Manhattan Pharmaceuticals Restless Legs Syndrome Product Offered
11.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 Manhattan Pharmaceuticals Main Business Overview
11.11.5 Manhattan Pharmaceuticals Latest Developments
12 Research Findings and Conclusion
Boehringer Ingelheim GmbH
UCB SA
Astellas
Arbor Pharmaceuticals
GlaxoSmithKline plc.
Ligand Pharmaceuticals Incorporated
axxonis Pharma AG
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
Omeros Corporation
Manhattan Pharmaceuticals
*If Applicable.